Analytical Data
-
基因名
SLC35F1
- Application
-
别名
SLC35F1; C6orf169; Solute carrier family 35 member F1
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q5T1Q4
-
表达区间
1-408 aa
-
氨基酸序列
MIPPEQPQQQLQPPSPAPPNHVVTTIENLPAEGSGGGGSLSASSRAGVRQRIRKVLNREMLISVALGQVLSLLICGIGLTSKYLSEDFHANTPVFQSFLNYILLFLVYTTTLAVRQGEENLLAILRRRWWKYMILGLIDLEANYLVVKAYQYTNLTSIQLLDCFVIPVVILLSWFFLLIRYKAVHFIGIVVCILGMGCMVGADVLVGRHQGAGENKLVGDLLVLGGATLYGISNVWEEYIIRTLSRVEFLGMIGLFGAFFSGIQLAIMEHKELLKVPWDWQIGLLYVGFSACMFGLYSFMQVVIKKTSATSVNLSLLTADLYSLFCGLFLFHYKFSGLYLLSFFTILIGLVLYSSTSTYIAQDPRVYKQFRNPSGPVVDLPTTAQVEPSVTYTSLGQETEEEPHVRVA
-
分子量
71.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC35F1, a member of the solute carrier family, has garnered attention in recent biological and medical research due to its potential role in cellular transport processes. This protein is primarily implicated in nucleotide-sugar transport across the cell membrane, a function that is crucial for glycoconjugate biosynthesis and cell signaling. Abnormal expression or dysfunction of SLC35F1 has been linked to various diseases, including certain cancers and metabolic disorders, making it a target of interest for therapeutic interventions. Recent studies have focused on the recombinant expression of SLC35F1 to better understand its structural and functional characteristics, as well as its interactions with other cellular components. By producing recombinant SLC35F1 in model systems, researchers aim to elucidate its mechanisms of action and regulatory pathways, which may pave the way for novel strategies in treating conditions influenced by glycosylation defects. The insights gained from studying SLC35F1 not only enhance our understanding of fundamental biological processes but also resonate with potential clinical applications, highlighting the importance of this transporter in health and disease.
